[
    {
        "text": "[Music] welcome to the drive podcast i'm your host peter attea if you like this video please let me know by subscribing to the channel or visiting my website to become a member for more exclusive content [Music] so let's talk a little bit about checkpoint inhibitors we they've come up now a couple of times in this discussion you've mentioned anti-ctla-4 and anti-pd1 [Music] certainly my time at the nci my second stint i got me got me very familiar with ntctla 4 and it was an exciting time um and of course james allison would go on to receive the nobel prize a couple of years ago for his work in the discovery of this maybe go back and explain how that system works how how the removal of brakes works um and and and of course as is part of the undercurrent of this it only works if there's a tumor antigen to be recognized in other words taking the brakes off when there's no stimuli doesn't do anything but how does that system work and how is it a two-edged sword so again there are stimulants and there are inhibitors of virtually every physiologic system that we have and one of the inhibitors are molecules on the cell surface on the surface of a lymphocyte that when engaged by a receptor will inhibit a lymphocyte from developing an immune reaction and surprisingly there are two molecules that have been found on the cell surface",
        "start": "00:00:00",
        "duration": 204.32,
        "title": "Checkpoint inhibitors in cancer therapy | Peter Attia, M.D. & Steven Rosenberg, M.D., Ph.D."
    },
    {
        "text": "now many more that when targeted by an antibody will not kill the cell but actually turn off the breaks that are keeping that cell's activity from exhibiting itself so it's releasing the breaks and it turns out to have a very important function in the body because there are some cells that can react against normal tissues that do not react because they're being inhibited by these breaks and when you release those breaks now the t cell can be very active and it turns out that cancer has manipulated those and by taking the breaks off you can attack certain cancers and explains why melanoma is one of the more common cancers to be attacked because it has so many antigens so many uh so many mutations and it was a startling discovery that simply attacking a molecule a single molecule on the cell surface could take the brakes off a lymphocyte and let it attack cancer and when it comes to melanoma kidney cancer cancers that have large numbers of mutations because they have mismatched repair gene mutations lynch syndrome the the msi the microsatellite unstable tumors they can very strongly react against cancer but the common epithelial cancers that result in 90 of deaths in patients have very little reactivity against the checkpoint modulator so although they can be life-saving and very likely although it's been too soon curable for some cancer patients the overwhelming majority of cancer",
        "start": "00:01:41",
        "duration": 209.91899999999993,
        "title": "Checkpoint inhibitors in cancer therapy | Peter Attia, M.D. & Steven Rosenberg, M.D., Ph.D."
    },
    {
        "text": "patients just do not respond to taking off the brakes because when you take off the brakes there's not a strong enough reaction to take to take advantage of but hopefully combinations of treatments using checkpoint modulators will be more effective in the future but it was a major a major step forward and the beauty of it easy to apply because all that required was the injection of an antibody [Music]",
        "start": "00:03:29",
        "duration": 60.839000000000006,
        "title": "Checkpoint inhibitors in cancer therapy | Peter Attia, M.D. & Steven Rosenberg, M.D., Ph.D."
    }
]